The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...
Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people w ...
PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a $77.5 million market cap company known for its focus on non-opioid pain management products, reported that the U.S. Food and Drug ...
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...